Patients with chronic liver disease and components of metabolic syndrome may be at higher risk for fibrosis.
Dr Stepanova and colleagues from Virginia, USA assessed the impact of clinicodemographic factors on hepatic fibrosis in chronic liver disease.
The team evaluated 1028 chronic liver disease patients, 964 in the analysis.
Extensive clinico-demographic and histological data were available.
Significant baseline fibrosis and fibrosis progression were compared between groups using univariate and multivariate analyses.
The researchers found that compared with hepatitis C and hepatitis B, NAFLD patients were more obese, diabetic, hypertensive and hyperlipidemic.
|Significant fibrosis occurred in 55% of hep C patients|
|Alimentary Pharmacology & Therapeutics|
Significant fibrosis occurred in 55%, 43% and 20% of hepatitis C, hepatitis B and NAFLD, respectively.
Factors independently associated with fibrosis in NAFLD included diabetes, elevated AST and ALT.
The research team found for viral hepatitis, independent predictors of fibrosis were low platelet count, age and elevated AST and ALT.
A second biopsy was available for 96 patients with follow-up of about 4 years.
The team noted that factors independently associated with progression of fibrosis were hepatitis C infection, higher ALT and lower platelet count.
Dr Stepanova's team concluded, “Diabetes mellitus is an independent risk factor for fibrosis only in NAFLD.”
“Elevated aminotransferases and/or low platelet counts are independently associated with significant baseline fibrosis or progression of fibrosis, in patients with chronic liver disease.”